Avectas is a cell engineering technology company, enabling the manufacture of cell therapies. The Company's technology, Solupore, delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of primary cell types including T-cells for immuno-oncology and gene editing applications. Avectas's approach makes cells extracted from a patient temporarily permeable, allowing for the introduction of edited DNA material.